Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Balicatib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK known ✓ | P43235 | 5/20 | 0.90 |
| ▸ | CTSB | P07858 | 18/20 | 0.90 |
| ▸ | CTSL | P07711 | 18/20 | 0.90 |
| ▸ | CTSS | P25774 | 16/20 | 0.90 |
| ▸ | CTSD | P07339 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Balicatib SCHEMBL1587772 | 0.95 | CTSB (1.00) | CTSBCTSLCTSSCTSKCTSD | |
| Fumaric Acid SCHEMBL1838249 | 0.87 | CTSL (0.67) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL4577128 | 0.87 | CTSL (0.85) | CTSBCTSLCTSSCTSKCTSD | |
| Fumaric Acid SCHEMBL1838246 | 0.87 | CTSL (0.67) | CTSBCTSLCTSSCTSKCTSD | |
| Fumaric Acid SCHEMBL4576164 | 0.86 | CTSB (0.67) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL25445621 | 0.85 | CTSB (0.82) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL4576796 | 0.85 | CTSB (0.82) | CTSBCTSLCTSSCTSKCTSD | |
| Maleic Acid SCHEMBL5565097 | 0.85 | CTSB (0.65) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL4576707 | 0.85 | CTSB (1.00) | CTSBCTSLCTSSCTSKCTSD | |
| SCHEMBL4577320 | 0.83 | CTSB (0.75) | CTSBCTSLCTSSCTSKCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135448-A1 | Use of cathepsin k inhibitors for treating of severe bone loss diseases | MISSBACH MARTIN | 2007-06-14 | — | — | US | claimed |
| EP-1686995-A1 | USE OF CATHEPSIN K INHIBITORS FOR TREATING OF SEVERE BONE LOSS DISEASES | Novartis AG (CH) | 2006-08-09 | — | — | EP | claimed |
| WO-2006063762-A1 | DIPEPTIDE NITRILES | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | claimed |
| WO-2005049028-A1 | USE OF CATHEPSIN K INHIBITORS IN SEVERE BONE LOSS DISEASES | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | claimed |
| WO-2006063762-A1 | DIPEPTIDE NITRILES | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135448-A1 | Use of cathepsin k inhibitors for treating of severe bone loss diseases | CTSK, CTSB, CTSZ | CTSK 1/4885CTSB 2/4885CTSL 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.